Correlation and Prognostic Value of Serum Soluble ICAM-1, Beta-2 Microglobulin, and IL-2αR Levels in Non-Hodgkin's Lymphoma

References

• The International Non‐Hodgkin's Lymphoma Prognostic Factors Proyect. A predictive model for aggressive non‐Hodgkin's lymphoma. New England Journal of Medicine 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Swan F., Jr, Velasquez W. S., Tucker S., Redman J. R., Rodriguez M. A., McLaughlin P., Hagemeister F. B., Cabanillas F. A new serologic staging system for large‐cell lym‐phomas based on initial beta 2‐microglobulin and lactate dehydrogenase levels. Journul of Clinical Oncology 1989; 7: 1518–1527
   PubMed Web of Science ®Google Scholar
• Coiffier B., Gisselbrecht C., Vose J. M., Tilly H., Herbre‐cht R., Bosly A., Armitage J. O., Groupe d'Etudes des Lymphomes Agressifs. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that colud identify patients requiring a more intensive therapy. Journal of Clinical Oncology 1991; 9: 211–219
   PubMed Web of Science ®Google Scholar
• Rubin L. A., Nelson D. L. The soluble interleukin‐2 receptor: biology, function, and clinical application. Annals of Internal Medicine 1990; 113: 619–627
   PubMed Web of Science ®Google Scholar
• Pizzolo G., Chilosi M., Semenzato G. The soluble interleukin‐2 receptor in haematological disorders. British Journal of Haematology 1987; 67: 377–380
   PubMed Web of Science ®Google Scholar
• Chilosi M., Semenzato G., Vinante F., Menestrina F., Piaz‐zola E., Focchiatti V., Sabbioni R., Zanotti R., Pizzolo G. Increased levels of soluble interleukin‐2 receptor in non‐Hodgkin lymphomas. Relationship with clinical, histo‐logic and phenotypic features. American Journal of Clinical Pathology 1989; 92: 186–191
   PubMed Web of Science ®Google Scholar
• Pui C. ‐H., Ip S. H., Kung P., Dodge R. K., Berard C. W., Crist W. M., Murphy S. B. High serum interleukin‐2 receptor levels are related to advanced disease and poor outcome in childhood non‐Hodgkin's lymphoma. Blood 1987; 70: 624–628
   PubMed Web of Science ®Google Scholar
• Wagner D. K., Kiwanuka J., Edwards B. K., Rubin L. A., Nelson D. L., Magrath I. T. Soluble interleukin‐2 receptor levels in patients with undifferentiated and lympho‐blastic lymphomas: correlation with survival. Journal of Clinical Oncology 1987; 5: 1262–1214
   PubMed Web of Science ®Google Scholar
• Hatlington D. S., Patil K., Lai P. K., Yasuda N. N., Armitage J. O., Ip S. H., Weisenburger D. D., Linder J., Purtilo D. T. Soluble interleukin 2 receptors in patients with maligant lymphoma. Archives of Pathology and Laboratory Medicine 1988; 112: 597–601
   PubMed Web of Science ®Google Scholar
• Stasi R., Zinzani P. L., Galieni P., Michele V., Damasio E., Dispensa E., Dammacco F., Papa G., Tura S. Prognostic value of serum IL‐10 and soluble IL‐2 receptor levels in aggressive nonHodgkin's lymphoma. British Journal of Haematology 1994; 88: 770–777
   PubMed Web of Science ®Google Scholar
• Barak V., Ginzburg M., Kalickam I., Polliack A. Serum soluble interleukin‐2 receptor levels are associated with clinical disease status and histopathological grade in non‐Hodgkin's lymphoma and chronic lymphocytic leukemia. Leukemia and Lymphoma 1992; 7: 431–438
   PubMed Web of Science ®Google Scholar
• Harabuchi Y., Kataura A., Irnai K. Circulating intercellular adhesion molecule‐1 and its cellular expression in head and neck non‐Hodgkin's lymphomas, includig lethal midline granuloma. Annals of Otology, Rhinology and Laryngology 1996; 105: 634–642
   PubMed Web of Science ®Google Scholar
• Musolino C., Alonci A., Allegra A., Spatari G., Bellomo G., Quartarone M. Serum levels of soluble ICAM‐1 in patients with malignant lymphoma in association with treatment response. British Journal of Haematology 1996; 94: 580–581
   PubMed Web of Science ®Google Scholar
• Christiansen I., Gidlöf C., Kalkner K. ‐M., Hagberg H., Bennmarker H., Tötterman T. Elevated serum levels of soluble ICAM‐1 in non‐Hodgkin's lymphomas with tnmour burden, disease activity and other prognostic markers. British Journal of Haematology 1996; 92: 639–646
   PubMed Web of Science ®Google Scholar
• Lister T. A., Crowther D., Sutcliffe S. B., Glatstein E., Canellos G. P., Young R. C., Rosemberg S. A., Coltman C. A., Tubiana M. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds Meeting. Journal of Clinical Oncology 1989; 7: 1630–1636
   PubMed Web of Science ®Google Scholar
• Lennert K., Feller A. C. Histopathologie des lymphomes malins non Hodgkiniens2 nd edn. Doin Editeurs, Pans 1991; 2G57
   Google Scholar
• Cavalli F. Chemotherapy of non‐Hodgkin's Lymphomas. Baillière's Clinical Haematology 1991; 4: 157–180
   PubMedGoogle Scholar
• Gearing A. J. H., Newman W. Circulating adhesion molecules in disease. Immunology Today 1993; 14: 506–512
   PubMedGoogle Scholar
• Heaney M. L., Golde D. W. Soluble cytokine receptors. Blood 1996; 87: 847–857
   PubMed Web of Science ®Google Scholar
• Smith K. A. Interleukin‐2: inception, impact, and implications. Science 1988; 240: 1169–1176
   PubMed Web of Science ®Google Scholar
• Salter D. M., Krajewski A. S., Sheehan T., Turner G., Guth‐hert J. G., Mclen A. Prognostic significance of activation and differentiation antigen expression in B‐cell non‐Hodgkin's lymphoma. Journal of Pathology 1989; 159: 211–220
   PubMed Web of Science ®Google Scholar
• Rubin L. A., Kurman C. C., Fritz M. E., Biddison W. E., Boutin B., Yarchoan R., Nelson D. L. Soluble interleukin‐2 receptors are released from activated human lym‐phoid cells in vitro. Journal of Immunology 1985; 135: 3172–3177
   PubMed Web of Science ®Google Scholar
• Carlos T. M., Harlan J. M. Leukocyte‐endothelial adhesion molecules. Blood 1994; 84: 2068–2101
   PubMed Web of Science ®Google Scholar
• Freedman A. S. Expression and function of adhesion receptors on normal B cells and B cell non‐Hodgkin's lymphomas. Seminars in Hematology 1993; 30: 318–28
   PubMed Web of Science ®Google Scholar
• Stauder R., Greil R., Schulz T. F., Thaler J., Gattgringer C., Radaskiewicz T., Dierich M. P., Huber H. Expression of leukocyte function‐associated antigen‐ and 7F7‐anti‐gen, and adhesion molecule related to intercellular adhesion molecule‐1 (ICAM‐1) in non‐Hodgkin's lymphomas and leu‐kemias: possible influence on growth patterns and leukemic behavior. Clinical and Experimental Immunology 1989; 77: 234–238
   PubMed Web of Science ®Google Scholar
• Terol M. ‐J., López‐Guillermo A., Bosch F., Villamor N., Cid M. ‐C., Rozman C., Campo E., Montserrat E. Expression of the adhesion molecule ICAM‐1 in non‐Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance. Journal of Clinical Oncology 1998; 16: 35–40
   PubMed Web of Science ®Google Scholar
• Rothlein R., Mainolfi E. A., Czajkowski M., Marlin S. D. A form of circulating ICAM‐1 in human serum. Journal of Immunology 1991; 147: 3788–3793
   PubMed Web of Science ®Google Scholar
• Seth R., Raymond F. D., Makgoba M. W. Circulating ICAM‐1 isoforms: diagnostic prospects for inflamatory and immune disorders. Lancet. 1991; 338: 83–84
   PubMed Web of Science ®Google Scholar
• Litam P., Swan R., Cabanillas F., Tucker S. L., McLaughin P., Hagemeister F. B., Rodriguez M. A., Velasquez W. S. Prognostic value of serum β‐2 microglobulin in low grade lymphoma. Annals of Internal Medicine 1991; 114: 855–860
   PubMed Web of Science ®Google Scholar